<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Tien D</submitter><funding>NIDDK NIH HHS</funding><funding>NIAID NIH HHS</funding><pubmed_abstract>&lt;h4>Background&lt;/h4>People with HIV (PWH) have experienced excess weight gain on tenofovir, lamivudine, and dolutegravir (TLD). The contribution of lifestyle behavior to this weight gain is poorly understood.&lt;h4>Methods&lt;/h4>The Population Effectiveness of Dolutegravir Implementation in sub-Saharan Africa (DISCO Study) was a prospective observational cohort study that followed participants in KwaZulu-Natal, South Africa, transitioning to TLD. Our primary outcome of interest was clinically significant weight gain, defined as ≥10% increase from baseline to 48 weeks. Primary exposures of interest were (1) fruit intake (servings/week), (2) vegetable intake (servings/week), (3) fast food intake frequency, (4) fried food intake frequency, (5) sugar-sweetened beverage (SSB) intake frequency, and (6</pubmed_abstract><journal>Journal of acquired immune deficiency syndromes (1999)</journal><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12924645</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Dolutegravir-based therapy, diet, physical activity and weight gain: a 48-week prospective cohort in South Africa.</pubmed_title><pmcid>PMC12924645</pmcid><funding_grant_id>K23 AI143470</funding_grant_id><funding_grant_id>K23 DK125162</funding_grant_id><funding_grant_id>P30 AI050409</funding_grant_id><pubmed_authors>Pillay D</pubmed_authors><pubmed_authors>Chandiwana N</pubmed_authors><pubmed_authors>Manne-Goehler J</pubmed_authors><pubmed_authors>Hedt-Gauthier B</pubmed_authors><pubmed_authors>Chen G</pubmed_authors><pubmed_authors>Siedner MJ</pubmed_authors><pubmed_authors>Tien D</pubmed_authors><pubmed_authors>Shazi G</pubmed_authors><pubmed_authors>Gupta RK</pubmed_authors><pubmed_authors>Moosa MS</pubmed_authors><pubmed_authors>McCluskey SM</pubmed_authors><pubmed_authors>Marconi VC</pubmed_authors><pubmed_authors>Venter WDF</pubmed_authors><pubmed_authors>Mabweazara S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Dolutegravir-based therapy, diet, physical activity and weight gain: a 48-week prospective cohort in South Africa.</name><description>&lt;h4>Background&lt;/h4>People with HIV (PWH) have experienced excess weight gain on tenofovir, lamivudine, and dolutegravir (TLD). The contribution of lifestyle behavior to this weight gain is poorly understood.&lt;h4>Methods&lt;/h4>The Population Effectiveness of Dolutegravir Implementation in sub-Saharan Africa (DISCO Study) was a prospective observational cohort study that followed participants in KwaZulu-Natal, South Africa, transitioning to TLD. Our primary outcome of interest was clinically significant weight gain, defined as ≥10% increase from baseline to 48 weeks. Primary exposures of interest were (1) fruit intake (servings/week), (2) vegetable intake (servings/week), (3) fast food intake frequency, (4) fried food intake frequency, (5) sugar-sweetened beverage (SSB) intake frequency, and (6</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-07-16T14:46:20.103Z</modification><creation>2026-07-09T11:01:08.519Z</creation></dates><accession>S-EPMC12924645</accession><cross_references><pubmed>41329528</pubmed><doi>10.1097/qai.0000000000003812</doi><doi>10.1097/QAI.0000000000003812</doi></cross_references></HashMap>